Novartis Foundation Symposium
Reversible Protein Acetylation
Herausgeber: Bock, Gregory R; Goode, Jamie A
Novartis Foundation Symposium
Reversible Protein Acetylation
Herausgeber: Bock, Gregory R; Goode, Jamie A
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
A comprehensive review of recent work on chromatin and non-histone proteins, this book arises from the interactions of a multidisciplinary group of scientists involved in the study of acetylation. This area of research opens up new and exciting possibilities for drug design, and so the final chapters in the book examine some of the potential applications in the treatment of various diseases.
Andere Kunden interessierten sich auch für
- Handbook of Proteins665,99 €
- David C. KilpatrickHandbook of Animal Lectins474,99 €
- Gerhard MichalBiochemical Pathways 2e145,50 €
- C. St. TsaiBiomacromolecules226,99 €
- RNA and DNA Editing248,99 €
- Thomas E. Creighton (Hrsg.)Encyclopedia of Molecular Biology, 4 Volume Set3.186,99 €
- Andrew D. MillerEssentials of Chemical Biology269,99 €
-
-
-
A comprehensive review of recent work on chromatin and non-histone proteins, this book arises from the interactions of a multidisciplinary group of scientists involved in the study of acetylation. This area of research opens up new and exciting possibilities for drug design, and so the final chapters in the book examine some of the potential applications in the treatment of various diseases.
Produktdetails
- Produktdetails
- Novartis Foundation Symposia 259
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 312
- Erscheinungstermin: 21. Mai 2004
- Englisch
- Abmessung: 235mm x 153mm x 19mm
- Gewicht: 622g
- ISBN-13: 9780470862612
- ISBN-10: 0470862610
- Artikelnr.: 14215293
- Novartis Foundation Symposia 259
- Verlag: Wiley & Sons
- 1. Auflage
- Seitenzahl: 312
- Erscheinungstermin: 21. Mai 2004
- Englisch
- Abmessung: 235mm x 153mm x 19mm
- Gewicht: 622g
- ISBN-13: 9780470862612
- ISBN-10: 0470862610
- Artikelnr.: 14215293
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.
Chair's Introduction (E. Verdin). Beyond the double helix: writing and
reading the histone code (Y. Wang, et al.). The indexing potential of
histone lysine methylation (G. Schotta, et al.) A model for step-wise
assembly of heterochromatin in yeast (D. Moazed, et al.). H2B
Ubiquitylation and deubiquitylation in gene activation (A. Wyce, et al.).
Structural and chemical basis of histone acetylation (R. Marmorstein).
Phosphorylation and acetylation of histone H3 at inducible genes: two
controversies revisted (L. Mahadevan, et al.). HDAC7 regulates apoptosis in
developing thymocytes (E. Verdin, et al.). Dual roles of histone
deacetylases in the control of cardiac growth (T. McKinsey and E. Olson).
Chromatin modifications as clues to the regulation of antigen receptor
assembly (D. Ciccone and M. Oettinger). General discussion I Histone
modifications in X inactivation. The HDAC complex and cytoskeleton (J.
Kovacs, et al.). Tat acetylation: a regulatory switch between early and
late phases in HIV transcription elongation (M. Ott, et al.). Dynamics of
the p53 acetylation pathway (W. Gu, et al.). Regulation of the NF-kB action
by reversible acetylation (W. Greene and L. Chen). General discussion II
p300 and DNA repair. Reversal of gene silencing as a therapeutic target for
cancer - roles for DNA methylation and interdigitation with chromatin (S.
Baylin). Transcription regulation by histone deacetylases (S. Wang, et
al.). Molecular and cellular basis for the anti-proliferative effects of
the HDAC inhibitor LAQ824 (P. Atadja, et al.). Histone deacetylase
inhibitors: development as cancer therapy (P. Marks, et al.). General
discussion III PML-RAR hypermethylation in leukemia. Index of Contributors.
Subject Index.
reading the histone code (Y. Wang, et al.). The indexing potential of
histone lysine methylation (G. Schotta, et al.) A model for step-wise
assembly of heterochromatin in yeast (D. Moazed, et al.). H2B
Ubiquitylation and deubiquitylation in gene activation (A. Wyce, et al.).
Structural and chemical basis of histone acetylation (R. Marmorstein).
Phosphorylation and acetylation of histone H3 at inducible genes: two
controversies revisted (L. Mahadevan, et al.). HDAC7 regulates apoptosis in
developing thymocytes (E. Verdin, et al.). Dual roles of histone
deacetylases in the control of cardiac growth (T. McKinsey and E. Olson).
Chromatin modifications as clues to the regulation of antigen receptor
assembly (D. Ciccone and M. Oettinger). General discussion I Histone
modifications in X inactivation. The HDAC complex and cytoskeleton (J.
Kovacs, et al.). Tat acetylation: a regulatory switch between early and
late phases in HIV transcription elongation (M. Ott, et al.). Dynamics of
the p53 acetylation pathway (W. Gu, et al.). Regulation of the NF-kB action
by reversible acetylation (W. Greene and L. Chen). General discussion II
p300 and DNA repair. Reversal of gene silencing as a therapeutic target for
cancer - roles for DNA methylation and interdigitation with chromatin (S.
Baylin). Transcription regulation by histone deacetylases (S. Wang, et
al.). Molecular and cellular basis for the anti-proliferative effects of
the HDAC inhibitor LAQ824 (P. Atadja, et al.). Histone deacetylase
inhibitors: development as cancer therapy (P. Marks, et al.). General
discussion III PML-RAR hypermethylation in leukemia. Index of Contributors.
Subject Index.
Chair's Introduction (E. Verdin). Beyond the double helix: writing and
reading the histone code (Y. Wang, et al.). The indexing potential of
histone lysine methylation (G. Schotta, et al.) A model for step-wise
assembly of heterochromatin in yeast (D. Moazed, et al.). H2B
Ubiquitylation and deubiquitylation in gene activation (A. Wyce, et al.).
Structural and chemical basis of histone acetylation (R. Marmorstein).
Phosphorylation and acetylation of histone H3 at inducible genes: two
controversies revisted (L. Mahadevan, et al.). HDAC7 regulates apoptosis in
developing thymocytes (E. Verdin, et al.). Dual roles of histone
deacetylases in the control of cardiac growth (T. McKinsey and E. Olson).
Chromatin modifications as clues to the regulation of antigen receptor
assembly (D. Ciccone and M. Oettinger). General discussion I Histone
modifications in X inactivation. The HDAC complex and cytoskeleton (J.
Kovacs, et al.). Tat acetylation: a regulatory switch between early and
late phases in HIV transcription elongation (M. Ott, et al.). Dynamics of
the p53 acetylation pathway (W. Gu, et al.). Regulation of the NF-kB action
by reversible acetylation (W. Greene and L. Chen). General discussion II
p300 and DNA repair. Reversal of gene silencing as a therapeutic target for
cancer - roles for DNA methylation and interdigitation with chromatin (S.
Baylin). Transcription regulation by histone deacetylases (S. Wang, et
al.). Molecular and cellular basis for the anti-proliferative effects of
the HDAC inhibitor LAQ824 (P. Atadja, et al.). Histone deacetylase
inhibitors: development as cancer therapy (P. Marks, et al.). General
discussion III PML-RAR hypermethylation in leukemia. Index of Contributors.
Subject Index.
reading the histone code (Y. Wang, et al.). The indexing potential of
histone lysine methylation (G. Schotta, et al.) A model for step-wise
assembly of heterochromatin in yeast (D. Moazed, et al.). H2B
Ubiquitylation and deubiquitylation in gene activation (A. Wyce, et al.).
Structural and chemical basis of histone acetylation (R. Marmorstein).
Phosphorylation and acetylation of histone H3 at inducible genes: two
controversies revisted (L. Mahadevan, et al.). HDAC7 regulates apoptosis in
developing thymocytes (E. Verdin, et al.). Dual roles of histone
deacetylases in the control of cardiac growth (T. McKinsey and E. Olson).
Chromatin modifications as clues to the regulation of antigen receptor
assembly (D. Ciccone and M. Oettinger). General discussion I Histone
modifications in X inactivation. The HDAC complex and cytoskeleton (J.
Kovacs, et al.). Tat acetylation: a regulatory switch between early and
late phases in HIV transcription elongation (M. Ott, et al.). Dynamics of
the p53 acetylation pathway (W. Gu, et al.). Regulation of the NF-kB action
by reversible acetylation (W. Greene and L. Chen). General discussion II
p300 and DNA repair. Reversal of gene silencing as a therapeutic target for
cancer - roles for DNA methylation and interdigitation with chromatin (S.
Baylin). Transcription regulation by histone deacetylases (S. Wang, et
al.). Molecular and cellular basis for the anti-proliferative effects of
the HDAC inhibitor LAQ824 (P. Atadja, et al.). Histone deacetylase
inhibitors: development as cancer therapy (P. Marks, et al.). General
discussion III PML-RAR hypermethylation in leukemia. Index of Contributors.
Subject Index.